Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Burger

Showing results (871-880 of 1,123) with videos related to

Pageof 113
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 6, 2023
Pharmacokinetic Data of Dolutegravir in Second-line Treatment of Children With Human Immunodeficiency Virus: Results From the CHAPAS4 TrialLisanne A H Bevers, Hylke Waalewijn, Alexander J Szubert, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 8, 2019
Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese IndividualsRoeland E Wasmann, Cornelis Smit, Eric P H van Dongen, et al.
AIDS (London, England)|April 11, 2006
The genotypic inhibitory quotient and the (cumulative) number of mutations predict the response to lopinavir therapyJolanda G M Hoefnagel, Manon J van der Lee, Peter P Koopmans, et al.
Antimicrobial Agents and Chemotherapy|August 21, 2020
Suboptimal Dosing of Fluconazole in Critically Ill Patients: Time To Rethink DosingEline W Muilwijk, Dylan W de Lange, Jeroen A Schouten, et al.
Therapeutic Drug Monitoring|December 31, 2010
Ribavirin plasma concentration measurements in patients with hepatitis C: early ribavirin concentrations predict steady-state concentrationsSerena Slavenburg, Hanneke W H A Huntjens-Fleuren, Ton S M Dofferhoff, et al.
Antiviral Therapy|April 28, 2006
Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005)Mark A Boyd, Preeyaporn Srasuebkul, Mana Khongphattanayothin, et al.
Antiviral Therapy|January 25, 2006
Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosisReshma S Autar, Ferdinand W N M Wit, Jongkol Sankote, et al.
AIDS (London, England)|July 17, 2007
Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patientsReshma Saskia Autar, Ferdinand W N M Wit, Jongkol Sankote, et al.
The American Journal of Cardiology|May 23, 2023
C-Reactive Protein and Risk of Cardiovascular Events and Mortality in Patients with Various Cardiovascular Disease LocationsPascal M Burger, Aruna D Pradhan, Jannick A N Dorresteijn, et al.
Journal of the American College of Cardiology|July 26, 2023
C-Reactive Protein and Risk of Incident Heart Failure in Patients With Cardiovascular DiseasePascal M Burger, Stefan Koudstaal, Arend Mosterd, et al.
Pageof 113

Showing results (871-880 of 1,123) with videos related to

Sort By:
Pageof 113
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 6, 2023
Pharmacokinetic Data of Dolutegravir in Second-line Treatment of Children With Human Immunodeficiency Virus: Results From the CHAPAS4 TrialLisanne A H Bevers, Hylke Waalewijn, Alexander J Szubert, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 8, 2019
Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese IndividualsRoeland E Wasmann, Cornelis Smit, Eric P H van Dongen, et al.
AIDS (London, England)|April 11, 2006
The genotypic inhibitory quotient and the (cumulative) number of mutations predict the response to lopinavir therapyJolanda G M Hoefnagel, Manon J van der Lee, Peter P Koopmans, et al.
Antimicrobial Agents and Chemotherapy|August 21, 2020
Suboptimal Dosing of Fluconazole in Critically Ill Patients: Time To Rethink DosingEline W Muilwijk, Dylan W de Lange, Jeroen A Schouten, et al.
Therapeutic Drug Monitoring|December 31, 2010
Ribavirin plasma concentration measurements in patients with hepatitis C: early ribavirin concentrations predict steady-state concentrationsSerena Slavenburg, Hanneke W H A Huntjens-Fleuren, Ton S M Dofferhoff, et al.
Antiviral Therapy|April 28, 2006
Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005)Mark A Boyd, Preeyaporn Srasuebkul, Mana Khongphattanayothin, et al.
Antiviral Therapy|January 25, 2006
Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosisReshma S Autar, Ferdinand W N M Wit, Jongkol Sankote, et al.
AIDS (London, England)|July 17, 2007
Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patientsReshma Saskia Autar, Ferdinand W N M Wit, Jongkol Sankote, et al.
The American Journal of Cardiology|May 23, 2023
C-Reactive Protein and Risk of Cardiovascular Events and Mortality in Patients with Various Cardiovascular Disease LocationsPascal M Burger, Aruna D Pradhan, Jannick A N Dorresteijn, et al.
Journal of the American College of Cardiology|July 26, 2023
C-Reactive Protein and Risk of Incident Heart Failure in Patients With Cardiovascular DiseasePascal M Burger, Stefan Koudstaal, Arend Mosterd, et al.
Pageof 113